![Kamran Alam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kamran Alam
Finanzdirektor/CFO bei
TAYSHA GENE THERAPIES, INC.
Vermögen: 8 Mio $ am 31.05.2026
Profil
Kamran Alam is currently Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. since 2020.
Former positions include Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. from 2019 to 2020, Vice President-Finance at Novartis Gene Therapies, Inc. from 2016 to 2019, Senior Director-Finance & Accounting at Aptinyx, Inc. from 2013 to 2016, and Finance Director at Naurex, Inc. Education includes an undergraduate degree from Stephen M.
Ross School of Business and an MBA from Kelley School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 1 341 600 ( 0,49 % ) | 8 Mio $ | 31.05.2026 |
Aktive Positionen von Kamran Alam
| Unternehmen | Position | Beginn |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Finanzdirektor/CFO | 01.08.2020 |
Ehemalige bekannte Positionen von Kamran Alam
| Unternehmen | Position | Ende |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 01.07.2020 |
| AVEXIS INC | Corporate Officer/Principal | 01.10.2019 |
| APTINYX | Comptroller/Controller/Auditor | 01.04.2016 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Corporate Officer/Principal | - |
Ausbildung von Kamran Alam
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
22
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Health Technology |
Stephen M. Ross School of Business
 Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
